For decades, cardiovascular care has focused on slowing disease and not reversing it. But new clinical data is challenging that paradigm.

In this episode, we break down emerging evidence showing that high-dose Nattokinase, a fibrinolytic enzyme derived from fermented soy, may do more than support heart health. It may actively reduce arterial plaque.

From a 36% reduction in carotid plaque size to insights into autophagy, inflammation, and the gut-heart axis, this episode explores what these findings really mean and where the science still needs scrutiny.

If you’re working in cardiovascular health, nutraceutical innovation, or clinical research, this is one conversation you don’t want to miss.